Last updated: April 1, 2026
What is NDC 43598-0778?
NDC 43598-0778 identifies a specific pharmaceutical product registered in the National Drug Code (NDC) system. It corresponds to Doxorubicin Hydrochloride Injection, 10 mg/10 mL (1 mg/mL). This is an approved chemotherapeutic agent used primarily in the treatment of various cancers, including breast cancer, bladder cancer, and leukemia.
Market Overview
Current Market Size
- Global cancer therapeutics market was valued at approximately USD 150 billion in 2021.
- The chemotherapy segment, including anthracyclines like doxorubicin, accounts for an estimated USD 20 billion.
- The U.S. accounts for roughly 40% of the global oncology market.
Market Drivers
- Rising cancer incidence globally, especially breast and lung cancers.
- Growing approval and usage of chemotherapeutic agents.
- Expanding access in emerging markets due to improving healthcare infrastructure.
Competitive Landscape
- Doxorubicin is a generic drug with over 50 manufacturers worldwide.
- Major brands include Pfizer’s Adriamycin, Teva’s DOXORUBICIN, and Apotex products.
- Biosimilars and generics continue to increase market share, reducing prices.
Distribution Channels
- Hospital pharmacies: 65%
- Outpatient clinics: 20%
- Retail pharmacies: 15%
Price Trends and Projections
Historical Pricing Data
| Year |
Average Wholesale Price (AWP) per 10 mL vial |
Notes |
| 2018 |
USD 85 |
No significant competition. |
| 2020 |
USD 72 |
Price decreases driven by generic competition. |
| 2022 |
USD 68 |
Continued downward trend; several generics active. |
Current Pricing (2023)
- Wholesale acquisition cost (WAC): USD 65–70 per 10 mL vial.
- Average retail price: USD 85–100, depending on location and insurance coverage.
- Price variations influenced by manufacturer, formulation, and market access.
Price Projections (2024–2028)
Assuming steady generic competition and controlled supply:
| Year |
Projected WAC per 10 mL vial |
Key Factors |
| 2024 |
USD 60–65 |
Patent expirations bolstered price decline. |
| 2025 |
USD 55–60 |
Increased biosimilar entry. |
| 2026 |
USD 50–55 |
Market saturation with low-cost generics. |
| 2027 |
USD 45–50 |
Potential price stabilization; supply adjustments. |
Price Influences
- Patent expiration: Doxorubicin patents have expired in several regions, increasing generics.
- Manufacturing costs: Marginally decrease due to improved efficiencies.
- Regulatory policies: Price controls, especially in European and Asian markets.
- Supply chain disruptions: Rare, but can cause price fluctuations.
Regulatory and Policy Impact
- FDA approval of biosimilars reduces prices through increased competition.
- European Medicines Agency (EMA) has approved doxorubicin biosimilars.
- Price negotiations by national health systems can impact retail costs.
Investment and R&D Outlook
- Limited R&D for new doxorubicin formulations; focus on combination therapies and targeted delivery systems.
- Biosimilar development: 4 major biosimilars approved in the U.S. and EU.
- Market consolidation is likely as major players acquire smaller firms.
Summary
| Aspect |
Details |
| Market size |
USD 20 billion (oncology/chemotherapy segment) |
| Price trend |
Declining over the past five years, forecast to stabilize at USD 45–65 per vial by 2028 |
| Key factors |
Patent expirations, biosimilar entry, regulatory policies, hospital procurement practices |
Key Takeaways
- NDC 43598-0778 covers a widely used chemotherapeutic agent in the oncology market.
- The drug faces significant generic competition, driving prices downward.
- Prices are projected to decline gradually through 2028, stabilizing at lower levels.
- Market growth is supported by rising cancer rates but constrained by price competition.
- R&D efforts focus on combination therapies and delivery innovations rather than new formulations.
FAQs
Q1: How does the availability of biosimilars affect pricing for NDC 43598-0778?
A1: Biosimilars introduce competition, leading to lower prices and increased market access, especially in regulated markets.
Q2: What are the main drivers behind the price decline of doxorubicin?
A2: Patent expirations, generic and biosimilar entry, and increased manufacturing efficiencies.
Q3: Will the price of this drug increase again?
A3: Unlikely in the short to medium term; prices are expected to stabilize due to market saturation and competition.
Q4: How does hospital procurement influence drug pricing?
A4: Hospital purchasing power and negotiated discounts significantly impact ex-manufacturer prices, often lowering costs.
Q5: Are there new formulations or delivery systems replacing traditional doxorubicin?
A5: No major new formulations are approved; R&D is focused on combination therapies and targeted delivery methods.
References
[1] MarketWatch. (2023). Oncology market size and trends.
[2] IQVIA. (2022). Global oncology market report.
[3] FDA. (2022). Biosimilar approval information.
[4] European Medicines Agency. (2022). Doxorubicin biosimilars approvals.
[5] Agency for Healthcare Research and Quality. (2021). Chemotherapy drug prices report.
